BlackRock Latin American Investment Trust plc (LON:BRLA) shares valuable insights in its latest portfolio update as of March 31, 2025. Discover performance highlights and asset details...
BlackRock Energy and Resources Income Trust plc (LON:BERI) shares its portfolio update as of March 31, 2025, highlighting market performance and investment strategies...
Discover the latest updates from BlackRock Income and Growth Investment Trust plc (LON:BRIG). Explore performance metrics and insights as of March 31, 2025...
Stay informed with the latest insights from VinaCapital Vietnam Opportunity Fund Limited's monthly report for March 2025, detailing key updates and shareholder information...
DCC plc has agreed to sell its healthcare division to HealthCo Investment for £1.05 billion, streamlining operations and enhancing shareholder value...
The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...
HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification...
Zotefoams plc has released its 2024 Annual Report and details for the 2025 AGM set for May 22, 2025. Discover key insights and compliance updates here...
BlackRock Latin American Investment Trust plc (LON:BRLA) shares valuable insights in its latest portfolio update as of March 31, 2025. Discover performance highlights and asset details...
BlackRock Energy and Resources Income Trust plc (LON:BERI) shares its portfolio update as of March 31, 2025, highlighting market performance and investment strategies...
Discover the latest updates from BlackRock Income and Growth Investment Trust plc (LON:BRIG). Explore performance metrics and insights as of March 31, 2025...
Stay informed with the latest insights from VinaCapital Vietnam Opportunity Fund Limited's monthly report for March 2025, detailing key updates and shareholder information...
DCC plc has agreed to sell its healthcare division to HealthCo Investment for £1.05 billion, streamlining operations and enhancing shareholder value...
The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...
HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification...
Zotefoams plc has released its 2024 Annual Report and details for the 2025 AGM set for May 22, 2025. Discover key insights and compliance updates here...
